Orthofix
This article was originally published in The Gray Sheet
Executive Summary
Thirteen-center U.S. safety and efficacy clinical trial of the firm's Cervical-Stim non-invasive bone growth stimulator is set to begin following investigational device exemption approval from FDA Sept. 27. The study will evaluate the device for increasing cervical fusion rates for high-risk patients who have a failure rate of up to 50% either from smoking or multi-level fusions, the firm says